Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone)
- PMID: 1590697
- PMCID: PMC189222
- DOI: 10.1128/AAC.36.1.39
Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone)
Abstract
Amphotericin B (AmB) has toxic effects and alters neutrophil (polymorphonuclear leukocyte [PMN]) function. A lipid-complexed formulation of AmB (AmB-LC) has been reported (A. S. Janoff, L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. Bonner, Proc. Natl. Acad. Sci. USA 85:6122-6126, 1988) to be less toxic than a desoxycholate-suspended preparation of AmB (AmB-des; Fungizone). In this study we compared the effects of AmB-des and AmB-LC on in vitro PMN function. Neither form of AmB stimulated PMN chemiluminescence, but AmB-des (2 micrograms/ml) nearly tripled PMN chemiluminescence in response to f-Met-Leu-Phe (fMLP), a phenomenon known as priming. Because AmB stimulates monocytes to release cytokines which can affect PMN function, we studied the effects of AmB on PMNs in mixed leukocyte cultures. AmB-des (1 to 2 micrograms/ml) increased the chemiluminescence of PMNs plus mixed mononuclear leukocytes (MNLs) to fMLP. The activity was about three times that of PMNs plus MNLs and seven times the activity of PMNs stimulated with fMLP in the absence of MNLs. Cell-free AmB-des (2 micrograms/ml)-stimulated, MNL-conditioned medium primed pure PMNs to a level equal to that of whole MNLs treated with AmB-des. AmB-LC was much less potent. AmB-LC (20 micrograms/ml) increased fMLP-stimulated chemiluminescence to two times that of PMNs plus MNLs without AmB-LC. AmB-des (2 micrograms/ml) (but not AmB-LC [2 micrograms/ml]) increased nitroblue tetrazolium reduction by PMNs in whole blood from 31 to 52% of positive cells. Neither form of AmB increased Mac-1 (the CD11b/CD18 integrin) expression of pure PMNs. AmB-des (0.5 to 2 micrograms/ml) (but not AmB-LC [< or = 40 micrograms/ml]) nearly doubled PMN Mac-1 expression in the presence of MNLs, and cell-free AmB-des (2 micrograms/ml)-stimulated, MNL-conditioned medium stimulated PMN Mac-1 to 125% of the control level. AmB-des (0.2 to 2 micrograms/ml) (but not AmB-LC [< or = 40 micrograms/ml]) decreased chemotaxis of pure PMNs to fMLP by as much as 35% and that of PMNs in the presence of MNLs by as much as 50%. Desoxycholate by itself had no effect on PMN function. These differences in activity between AmB-des and AmB-LC may explain the lessened toxicity observed with AmB-LC.
Similar articles
-
Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.Antimicrob Agents Chemother. 1992 Feb;36(2):408-16. doi: 10.1128/AAC.36.2.408. Antimicrob Agents Chemother. 1992. PMID: 1318681 Free PMC article.
-
The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity.Blood. 1993 Apr 1;81(7):1863-70. Blood. 1993. PMID: 7681704
-
Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice.Antimicrob Agents Chemother. 1993 Dec;37(12):2716-21. doi: 10.1128/AAC.37.12.2716. Antimicrob Agents Chemother. 1993. PMID: 8109941 Free PMC article.
-
Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index.Curr Pharm Des. 2016;22(7):792-803. doi: 10.2174/1381612822666151209151719. Curr Pharm Des. 2016. PMID: 26648472 Review.
-
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48. Oncol Nurs Forum. 1998. PMID: 9460772 Review.
Cited by
-
Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes.Antimicrob Agents Chemother. 1994 Nov;38(11):2605-11. doi: 10.1128/AAC.38.11.2605. Antimicrob Agents Chemother. 1994. PMID: 7872755 Free PMC article.
-
Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.Antimicrob Agents Chemother. 2002 Jun;46(6):1974-6. doi: 10.1128/AAC.46.6.1974-1976.2002. Antimicrob Agents Chemother. 2002. PMID: 12019118 Free PMC article.
-
Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.Antimicrob Agents Chemother. 2006 Mar;50(3):868-73. doi: 10.1128/AAC.50.3.868-873.2006. Antimicrob Agents Chemother. 2006. PMID: 16495244 Free PMC article.
-
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.Front Microbiol. 2012 Aug 8;3:286. doi: 10.3389/fmicb.2012.00286. eCollection 2012. Front Microbiol. 2012. PMID: 23024638 Free PMC article.
-
Carrier effects on biological activity of amphotericin B.Clin Microbiol Rev. 1996 Oct;9(4):512-31. doi: 10.1128/CMR.9.4.512. Clin Microbiol Rev. 1996. PMID: 8894350 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous